Home > Keywords >
| Catalog | name | Description | price |
|---|---|---|---|
| R-R-2138 | Trimetazidine-d8 dihydrochloride CAS No.1219795-37-5 | Trimetazidine-d8 (dihydrochloride)/CAS No.1219795-37-5 is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor. | price> |
| R-C-439 | gsk1904529A | Gsk-1904529a is an IGF-1R inhibitor,which has broad application prospects in the treatment of igf-ir-dependent tumors.Gsk1904529a selectively inhibited IGF-IR and IR with IC50 of 27 and 25 nmol/L,respectively.Gsk1904529a blocks autophosphorylation and downstream signal transduction of receptor,leading to cell cycle arrest.It inhibits the proliferation of cell lines from solid and hematological malignancies.Multiple myeloma and Ewing sarcoma cell lines are the most sensitive. | price> |
| R-R-2139 | PI-1840 CAS No.1401223-22-0 | PI-1840/CAS No.1401223-22-0 is a potent and selective chymotrypsin-like (CT-L) inhibitor for with an IC50 value of 27 nM. PI-1840 inhibits cell proliferation and arrest cell cycle at G2/M phase. PI-1840 induces apoptosis and induces autophagy. PI-1840 induces the accumulation of proteasome substrates p27, Bax, and IκB-α. | price> |
| R-C-440 | LY2157299 | Galunisertib(LY2157299)is selective TGF-receptor kinase inhibitor.Galunisertib was found to inhibit the growth in an in vitro clonogenic assay in 6.3%(5/79)of the examined PDX. | price> |
| R-R-2140 | CUR5g CAS No.1370032-20-4 | CUR5g/CAS No.1370032-20-4 is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo. | price> |
| R-C-441 | DMXAA(AS1404,ASA404) | DMXAA is an apoptosis inducer,and an anti-vascular.DMXAA is an inhibitor of NQO1, Flk-1 and Flt-1. | price> |
| R-R-2141 | GW406108X CAS No.1644443-92-4 | GW406108X/CAS No.1644443-92-4 is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK. | price> |
| R-C-442 | Brivanib(bms-540215) | Brivanib is an ATP-competitive inhibitor against human Flk-1(VEGFR-2)and mouse Flk-1 with IC50 of 25 nM and 89 nM,respectively.Brivanib also inhibits Flt-1 (VEGFR-1)and Flg (FGFR-1) with IC50 of 0.38 and 0.148 μM.Brivanib displays antitumor activities in H3396 xenograft.This compound completely inhibits the tumor growth,with TGI of 85% and 97%, respectively. | price> |
| R-R-2142 | Manzamine A hydrochloride CAS No.104264-80-4 | Manzamine A hydrochloride/CAS No.104264-80-4, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1. | price> |
| R-C-443 | Brivanib alaninate(BMS-582664) | Brivanib Alaninate is the alaninate salt of a vascular endothelial growth factor receptor 2(VEGFR2) inhibitor with potential antineoplastic activity.Brivanib strongly binds to and inhibits VEGFR2,a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells;inhibition of VEGFR2 may result in inhibition of tumor angiogenesis,inhibition of tumor cell growth,and tumor regression. | price> |
| R-R-2143 | Vacuolin-1 CAS No.351986-85-1 | Vacuolin-1/CAS No.351986-85-1 is a potent and cell-permeable lysosomal exocytosis inhibitor. Vacuolin-1 blocks the Ca2+-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. vacuolin‐1 is a potent and selective PIKfyve inhibitor and inhibits late‐stage autophagy by impairing lysosomal maturation. Vacuolin-1 can induce vacuole formation and increase the percentage of enucleated cells. | price> |
| R-C-444 | vx-702 | VX-702 inhibits p38 MAPK, preventing p38 MAPK-dependent inflammatory cytokine release.VX-702 is in development to treat inflammation and cardiovascular diseases and currentlyshows mixed results in clinical trials as a potential treatment for rheumatoid arthritis.In vitro,Vx-702 decreases platelet lesioning in storage without affecting platelet function. | price> |
| R-R-2144 | Gefitinib-d3 CAS No.1173976-40-3 | Gefitinib-d3 (ZD1839-d3)/CAS No.1173976-40-3 is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity. | price> |
| R-C-445 | Linifanib (ABT-869) | Linifanib(ABT-869) is a novel,potent ATP-competitive VEGFR/PDGFR inhibitor for KDR(IC50:4 nM),CSF-1R (IC50:3 nM),Flt-1/3(IC50:3/4 nM)and PDGFRβ(IC50:66 nM).Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases,such as FMS-related tyrosine kinase receptor-3 (FLT3). | price> |
| R-R-2145 | NL-1 CAS No.188532-26-5 | NL-1/CAS No.188532-26-5 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway. | price> |
| R-C-446 | Marbofloxacin | Marbofloxacin is a potent antibiotic inhibiting bacterial DNA replication. | price> |
| R-R-2146 | Acetyl Coenzyme A trisodium CAS No.102029-73-2 | Acetyl-coenzyme A (Acetyl-CoA) trisodium/CAS No.102029-73-2 is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis. | price> |
| R-C-447 | Moxifloxacin | Moxifloxacin(BAY12-8039)is a fourth-generation synthetic fluoroquinolone antibacterial agent.Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis,acute bacterial exacerbations of chronic bronchitis,and community-acquired pneumonia. | price> |
| R-R-2147 | Dimethyl fumarate-d2 CAS No.23057-98-9 | Dimethyl fumarate-d2/CAS No.23057-98-9 is the deuterium labeled Dimethyl fumarate. Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research. | price> |
| R-C-448 | NPS-2143 | Nps-2143(sb-262470a),an oral active calcium solubilizer,is a selective calcium sensitive receptor(CaSR)antagonist.Nps-2143(sb-262470a)increased the cytosolic Ca2+concentration (IC50=43 nm) by activating Ca2+receptor in HEK 293 cells expressing human Ca2 + receptor. | price> |

Items-$0.00

Email:
Tel.:
RuixiBiotechCo.Ltd /KamulinBiotechco.ltd
Add: Room 20F 2002, Meiyuan Building, Yanta District, Xi’ an City, Shaanxi Province 710061 China
Tel: 02988811435
Fax: (86-29)8881-1435
Email: sales@ruixibiotech.com
Web: http://www.ruixibiotech.com


